EU Joint Clinical Assessments under the HTA Regulation: 2026 market access guide

If a biopharma market-access team is preparing an European Medicines Agency (EMA) submission for a new oncology drug or advanced therapy medicinal product (ATMP) in 2026, its regulatory and evidence timeline is no longer governed solely by central scientific review in Amsterdam. Under Regulation (EU) 2021/2282 on Health Technology Assessment, mandatory EU-level Joint Clinical Assessments (JCAs) took effect on 12 January 2025. As of May 2026, 16 JCA procedures had been formally initiated across member states: 14 ongoing assessments, 1 completed assessment (tovorafenib, led by Ireland's National Centre for Pharmacoeconomics (NCPE) with Germany's IQWiG as co-assessor, endorsed 4 May 2026), and 1 discontinued procedure (sasanlimab in non-muscle invasive bladder cancer, following marketing authorization withdrawal).

Of the 14 ongoing assessments, 13 (93 percent) focus on oncology indications, with lung cancer representing the largest single clinical cluster (n=5). The two non-oncology assessments are both advanced therapy medicinal products (ATMPs), targeting spinal muscular atrophy and respiratory papillomatosis. From June 2026, the framework expands to high-risk medical devices (Class IIb and III devices and Class D in vitro diagnostics), followed by orphan medicinal products in January 2028 and all centrally authorised medicines by January 2030. Because member state Health Technology Assessment (HTA) bodies must give due consideration to the final EU Joint Clinical Assessment report as the shared clinical basis for their national pricing and reimbursement (P&R) proceedings — and cannot require manufacturers to duplicate the baseline clinical analyses, though they may supplement with additional national clinical data — biopharma access leads must realign global phase 3 trial design, comparative effectiveness evidence, and sub-population analyses to survive multi-country PICO (Population, Intervention, Comparator, Outcome) consolidation.

+---------------------------------------------------------------------------------------------------+
|                        EU JOINT CLINICAL ASSESSMENT (JCA) TIMELINE & SCOPE                        |
+---------------------------------------------------------------------------------------------------+
|                                                                                                   |
|   JAN 12, 2025                JUNE 2026                  JAN 1, 2028               JAN 1, 2030    |
|   ┌──────────────────────┐    ┌──────────────────────┐   ┌──────────────────────┐  ┌─────────────┐ |
|   │  Oncology & ATMPs    │───>│  High-Risk Devices   │──>│   Orphan Medicines   │─>│ All Central │ |
|   │  • 16 Initiated      │    │  • Class IIb/III     │   │   • Mandatory JCA    │  │ Medicines   │ |
|   │  • 14 Ongoing        │    │  • Class D IVDs      │   │   • Sub-population   │  │ • Full EU   │ |
|   │  • 93% Oncology      │    │  • ~5 Initial Cases  │   │     PICO Scoping     │  │   Scope     │ |
|   └──────────────────────┘    └──────────────────────┘   └──────────────────────┘  └─────────────┘ |
|                                                                                                   |
|    dossiers submitted via EU HTA IT Platform in parallel with EMA Centralized MAA                 |
|    PICO consolidation window: 60-day to 100-day dossier assembly post-scoping                     |
+---------------------------------------------------------------------------------------------------+

---

What is a Joint Clinical Assessment and when does it apply?

Regulation (EU) 2021/2282 creates a centralized EU-level framework for assessing the relative clinical efficacy and relative clinical safety of health technologies. Before 2025, a drug developer launching across the European Union faced 27 separate national HTA submissions—ranging from Germany's AMNOG (G-BA/IQWiG) and France's HAS (CT) to Spain's IPT and Italy's AIFA—each issuing divergent comparator requests, outcome definitions, and indirect treatment comparison (ITC) requirements.

The EU HTA Regulation replaces redundant national clinical evaluations with a single, joint assessment conducted by the HTA Co-operation Group (HTACG), composed of member state HTA representatives. Crucially, the JCA evaluates clinical domains only:

1. Target health condition and current clinical management.
2. Technical characteristics and relative clinical effectiveness.
3. Relative safety and adverse event profiles.

Non-clinical domains—specifically economic evaluations, cost-effectiveness modeling, budget impact analysis, national pricing negotiations, and reimbursement decisions—remain strictly under national sovereignty. Member states retain full authority to decide whether to list a medicine or set its price. However, national HTA bodies are legally required to accept the final JCA report as the clinical basis for their national pricing and reimbursement proceedings and cannot request duplicate baseline clinical analyses.

---

Which products are in the JCA pipeline right now and who assesses them?

Tracking the live pipeline of Joint Clinical Assessments provides critical foresight into how the HTACG assigns assessor and co-assessor roles among national HTA authorities. Analysis of the published EU Commission JCA register and IQWiG operational disclosures reveals 16 total procedures initiated between January 2025 and May 2026:

Of the 14 active assessments, 13 focus on oncology or hematology, confirming that the first wave of EU HTA reform is almost entirely an oncology access event. Lung cancer alone accounts for 5 of the 14 ongoing evaluations (about a third), establishing standard-of-care benchmark precedents across ROS1, ALK, and DLL3 targets. Germany, acting through IQWiG, serves as lead assessor on four of the ongoing JCAs, and the full pipeline spans nine assessor countries and thirteen co-assessor countries, reflecting the deliberately EU-wide allocation of work.

The completion of the first JCA for tovorafenib on 4 May 2026 — led by Ireland's NCPE with Germany's IQWiG producing the report as co-assessor — demonstrated that joint assessment timelines can hold under operational pressure; HTACG endorsement followed roughly 10 days after the European Commission's conditional authorization. Conversely, the discontinuation of sasanlimab after marketing authorization withdrawal highlights that global regulatory attrition directly impacts the JCA docket.

---

What are the PICO scoping and dossier-day timeline rules?

The central strategic challenge of the EU JCA framework is the PICO Scoping Phase. Because member states maintain different standard-of-care regimens, clinical guidelines, and reimbursement environments, no single country's preferred comparator or patient subgroup satisfies all 27 nations.

Under Article 8 of Regulation (EU) 2021/2282, the HTACG compiles national PICO requests from all participating member states into a consolidated PICO Scoping Document.

                                  EU JCA DOSSIER TIMELINE
                                  
 EMA Validation (Day 0)
        │
        ▼
 PICO Scoping Survey to 27 Member States (Day 1 - Day 30)
        │
        ▼
 HTACG Consolidates PICO Scoping Document (Day 30 - Day 60)
        │
        ▼
 Final PICO Issued to Health Technology Developer (HTD)
        │
        ├───────────────────────────────────────────────────────┐
        ▼                                                       ▼
 Standard JCA Submission Window                       Accelerated Review Window
 100 Days Post-PICO Receipt                           60 Days Post-PICO Receipt
        │                                                       │
        ▼                                                       ▼
 Joint Assessment Drafted by Lead Assessor & Co-Assessor (140 Days)
        │
        ▼
 HTACG Review, Fact-Checking & Final Approval
        │
        ▼
 Publication on EU HTA IT Platform (Within 30 Days of EMA CHMP Opinion)

The PICO consolidation process enforces strict operational constraints:

• Multiple PICO Piles: A manufacturer rarely receives a single PICO. In oncology trials, it is common to receive between 4 and 12 distinct PICO questions reflecting regional variations (e.g., chemo-immunotherapy combination vs. monotherapy vs. targeted agent).
• 60 vs. 100 Dossier Days: Under the JCA Implementing Act, once the Commission requests the dossier the Health Technology Developer (HTD) has 100 calendar days for a new medicinal product, or 60 calendar days for accelerated EMA procedures and variation procedures (for example, new indications), to assemble and submit the full JCA dossier. Extensions toward the hard HTAR deadline — no later than 45 days before the expected CHMP opinion — are possible only in justified cases with assessor consent.
• No New Trial Data: The JCA dossier must rely strictly on evidence available at the time of EMA filing. Manufacturers cannot run new randomized controlled trials (RCTs) during the 100-day window; they must execute network meta-analyses (NMAs), matching-adjusted indirect comparisons (MAICs), or real-world evidence (RWE) syntheses to address every requested PICO.

---

How do the 2026 medical-device expansion and the 2028/2030 scope changes affect planning?

The implementation of Regulation (EU) 2021/2282 follows a strict statutory phase-in schedule designed to build operational capacity within the HTACG:

1. January 12, 2025: Mandatory JCAs for all new medicinal products with a new active substance indicated for oncology and all Advanced Therapy Medicinal Products (ATMPs).
2. June 2026 (Medical Device Expansion): Mandatory joint clinical assessments begin for selected high-risk medical devices (Class IIb and Class III devices under Regulation (EU) 2017/745) and high-risk in vitro diagnostic devices (Class D IVDs under Regulation (EU) 2017/746). According to the HTACG 2026 Work Programme published in late 2025, approximately 5 high-risk device and diagnostic assessments are slated for initial scoping in H2 2026.
3. January 1, 2028: Mandatory expansion to all orphan medicinal products. Orphan drug developers—who previously benefited from flexible national HTA timelines—will face centralized PICO scoping and strict comparative evidence standards.
4. January 1, 2030: Universal coverage. All centrally authorised medicinal products entering the EU market will undergo mandatory JCA.

For pharma portfolio leads, this phased expansion requires immediate trial protocol modifications. Phase 3 pivotal trials designed in 2026 for 2028 or 2030 submission must pre-emptively include European regional comparators and predefined subgroup stratifications to avoid failing future PICO consolidations.

---

How does EU JCA compare with national HTA such as NICE, and what stays national?

To understand the scale and velocity of the EU JCA framework, biopharma strategists should benchmark EU joint output against established single-country HTA bodies.

In the United Kingdom, the National Institute for Health and Care Excellence (NICE) maintains a comprehensive guidance catalog comprising 1,648 total guidance records, of which 898 are Technology Appraisals (TAs). NICE averages between 70 and 90 completed Technology Appraisals per year, covering cost-effectiveness thresholds (£20,000–£30,000 per QALY), commercial access agreements, and Managed Access Fund placements.

By contrast, the EU JCA framework operates at a different tier of the European market-access architecture:

While NICE issues a clear "recommended" or "not recommended" determination tied to NHS funding, the EU JCA report contains no clinical recommendation or score. It provides a neutral, multi-comparator summary of clinical evidence across all national PICO requests.

When the JCA report is published on the EU HTA IT Platform, national market-access teams must immediately take the document into 27 separate national pricing and reimbursement negotiations.

For instance, Germany's G-BA will use the JCA clinical data to assign an added benefit category (Zusatznutzen), France's HAS will use it to determine the Amélioration du Service Médical Rendu (ASMR) rating, and Italy's AIFA will incorporate it into regional formulary positioning.

Biopharma teams that cross-reference our by-the-numbers look at EU CTIS clinical trials alongside our NICE technology appraisals by the numbers will recognize that while CTIS harmonizes trial authorization and NICE governs UK cost-effectiveness, the EU JCA sits squarely in the middle—forcing biopharma to align EU trial evidence with member state clinical preferences years before approval. Furthermore, teams building global dossiers should align their European PICO strategy with our analysis of AMCP dossier evidence gaps to ensure U.S. and EU payer requirements do not pull phase 3 trial design in contradictory directions.

---

Frequently Asked Questions

Does the JCA replace national pricing and reimbursement decisions in each member state?

No. Regulation (EU) 2021/2282 explicitly reserves pricing and reimbursement authority to individual member states. The JCA harmonizes only the relative clinical evaluation (efficacy and safety). Each country continues to conduct its own economic modeling, budget impact analysis, and price negotiations. However, member states are legally prohibited from requesting baseline clinical assessments that duplicate the published JCA report.

What is the 60-day versus 100-day JCA dossier submission window?

Once the Commission requests the JCA dossier, the standard submission deadline under the JCA Implementing Act is 100 calendar days for a new medicinal product. For accelerated EMA procedures and variation procedures (such as a new-indication application), the window is compressed to 60 calendar days. Either deadline is ultimately bounded by the HTAR rule that the JCA report be ready no later than 45 days before the expected CHMP opinion. Access teams must prepare template comparative analyses well in advance of the dossier request.

Why was the first completed JCA tovorafenib, and what does that signal?

Tovorafenib (Ojemda)—a type II RAF inhibitor indicated for pediatric low-grade glioma—was the first JCA to reach completion, endorsed by the Coordination Group on 4 May 2026. The assessment was led by Ireland's NCPE, with Germany's IQWiG producing the report as co-assessor. Its status as the first completed procedure demonstrates that rare pediatric oncology indications with single-arm trial data and historical control cohorts can navigate the EU JCA review process within statutory timelines.

How many JCAs were expected in 2026 versus how many actually started?

The HTACG 2026 Work Programme anticipated approximately 50 joint assessment procedures initiating throughout 2026 as EMA oncology filings accelerate. By May 2026, 16 total procedures had been initiated. The gap reflects regulatory submission timing and EMA validation schedules, with heavy filing volume expected in H2 2026.

---

Sources

1. European Commission (DG Health and Food Safety): EU Health Technology Assessment Regulation (Regulation (EU) 2021/2282). Official Journal of the European Union. Accessible at: https://health.ec.europa.eu/medicinal-products/eu-health-technology-assessment-regulation_en
2. EUR-Lex: Regulation (EU) 2021/2282 of the European Parliament and of the Council of 15 December 2021 on health technology assessment. Accessible at: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32021R2282
3. European Commission: Commission Implementing Regulation (EU) 2024/1381 of 23 May 2024 laying down the procedural rules for joint clinical assessments. (Sets the 100-day standard and 60-day accelerated/variation dossier submission windows.)
4. HTA Co-operation Group (HTACG): 2026 Work Programme for the Implementation of Regulation (EU) 2021/2282. Published 28 November 2025.
5. Institute for Quality and Efficiency in Health Care (IQWiG): First Joint Clinical Assessment completed under EU HTA Regulation (Tovorafenib). Press Release & Operational Statement, 4 May 2026.
6. ISPOR (International Society for Pharmacoeconomics and Outcomes Research): Implementation Status of EU Joint Clinical Assessments: Procedure Tracking and Assessor Allocations (16 procedures, 9 assessor and 13 co-assessor countries, as of 4 May 2026). May 2026.
7. SSI Strategy: Joint Clinical Assessments — Mandatory EU-Level HTA and the PICO/Dossier-Day Operating Rules. February 2025.
8. National Institute for Health and Care Excellence (NICE): NICE Guidance Catalog & Technology Appraisal Registry. Dataset snapshot, June 2026.
9. National Institutes of Health (PMC): Implementing the EU HTA regulation and joint clinical assessment: a multi-stakeholder perspective. BMC Health Services Research / PubMed Central. Accessible at: https://ncbi.nlm.nih.gov/pmc/articles/PMC13078104/
10. ClinicalTrials.gov: FIREFLY-1 Phase 2 Study of Tovorafenib (DAY101) in Pediatric Low-Grade Glioma. U.S. National Library of Medicine. Accessible at: https://clinicaltrials.gov/study/NCT04775485